Related Experiment Video

Updated: Apr 26, 2026

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

2.8K

Can MII-pH values predict the duration of treatment for GERD in preterm infants?

Domenico Umberto De Rose1, Francesco Cresi2, Valerio Romano1

  • 1Division of Neonatology, Department of Pediatrics, Catholic University of Sacred Heart, Rome, Italy.

Early Human Development
|July 23, 2014
PubMed

Insights

Multichannel Intraluminal Impedance (MII) parameters show prognostic value for predicting the duration of Gastro-Esophageal Reflux Disease (GERD) treatment in preterm infants. These MII findings can guide therapy duration, offering a new diagnostic and prognostic tool.

Area of Science:

  • Neonatal Medicine
  • Gastroenterology
  • Pediatric Surgery

Background:

  • Gastro-Esophageal Reflux Disease (GERD) is common in preterm infants.
  • The prognostic role of Multichannel Intraluminal Impedance and pH monitoring (MII/pH) in preterm infants with GERD is not well understood.
  • Early identification of prognostic indicators can optimize treatment strategies.

Purpose of the Study:

  • To investigate the relationship between MII/pH variables and the duration of pharmacological therapy for GERD.
  • To assess the prognostic value of MII/pH parameters in preterm infants (gestational age ≤34 weeks).

Main Methods:

  • Retrospective review of preterm infants (GA ≤34 weeks) treated for GERD.
  • MII/pH monitoring data and duration of pharmacological therapy were collected.
  • Linear regression models analyzed MII/pH parameters as independent variables and treatment duration as the dependent variable.

Main Results:

  • Significant correlations were found between treatment duration and MII-BEI (r(2)=0.36, p=0.01) and MII-reflux frequency (r(2)=0.33, p=0.02).
  • Weakly acidic reflux events showed strong correlations: MII-w.ac.BEI (r(2)=0.26, p=0.05), MII-w.ac. reflux frequency (r(2)=0.44, p=0.01), and MII-proximal w.ac. reflux frequency (r(2)=0.35, p=0.02).
  • No significant correlation was observed between pH-Reflux Index and treatment duration.

Conclusions:

  • MII parameters demonstrate potential prognostic value in preterm infants with GERD.
  • MII findings may help predict the required duration of pharmacological treatment.
  • This suggests MII can serve as both a diagnostic and prognostic tool in this population.
Abstract

Keywords:
GERDMII/pHNewbornsPreterm infants

More Related Videos

Probiotic Studies in Neonatal Mice Using Gavage10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

21.0K
Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture05:33

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture

Published on: August 4, 2023

2.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.1K
Gastroesophageal Reflux Disease01:25

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is the backward flow of stomach contents (acid, pepsin, or bile) into the esophagus, causing mucosal inflammation known as esophagitis. It results from failure of antireflux mechanisms, mainly the lower esophageal sphincter (LES), influenced by mechanical and physiological factors.Etiology and Risk FactorsGERD develops when LES function is weakened or when intra-abdominal pressure increases. Risk factors include aging, obesity, and sliding hiatal hernia,...
38
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
798
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405